drugset / Trial / NCT00966602

Drug-Drug Interaction Study of VX-809 and VX-770 in Healthy Subjects

NCT00966602

Phase 1 Completed 24 enrolled Vertex Pharmaceuticals Incorporated
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to assess the pharmacokinetics and safety of co-administration of VX-770 and VX-809 in healthy adults.

Timeline

Start
2009-09
Primary completion
2009-12
Completion
2009-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Ivacaftor Other / unclassified Oral
Subject Lumacaftor Small molecule Oral

Indications